WeLeader Biomedical Past Earnings Performance

Past criteria checks 2/6

WeLeader Biomedical has been growing earnings at an average annual rate of 6.3%, while the Healthcare industry saw earnings growing at 7.1% annually. Revenues have been declining at an average rate of 3.2% per year. WeLeader Biomedical's return on equity is 21.7%, and it has net margins of 15.8%.

Key information

6.3%

Earnings growth rate

-14.9%

EPS growth rate

Healthcare Industry Growth	9.1%
Revenue growth rate	-3.2%
Return on equity	21.7%
Net Margin	15.8%
Last Earnings Update	30 Sep 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How WeLeader Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TPEX:7713 Revenue, expenses and earnings (TWD Millions)
Date	Revenue	Earnings	G+A Expenses
30 Sep 23	955	151	98
30 Jun 23	952	146	98
31 Mar 23	994	150	97
31 Dec 22	1,036	154	97
31 Dec 21	841	106	87

Quality Earnings: 7713 has a high level of non-cash earnings.

Growing Profit Margin: 7713's current net profit margins (15.8%) are higher than last year (14.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 7713's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare 7713's past year earnings growth to its 5-year average.

Earnings vs Industry: 7713 earnings growth over the past year (6.3%) did not outperform the Healthcare industry 7.2%.

Return on Equity

High ROE: 7713's Return on Equity (21.7%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/01 00:18
End of Day Share Price	2025/01/22 00:00
Earnings	2023/09/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

WeLeader Biomedical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution